Your Article Summary
See Latest ArticlesProtox to Present Benign Prostatic Hyperplasia Data at Canadian Urology Conference
Protox Therapeutics , 06/30/09
Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, announced that data from their open label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia, will be presented this afternoon at the 64th Annual Meeting of the Canadian Urological Association. The 2009 CUA Meeting is the country's largest gathering of urology professionals taking place at the Westin Harbour Castle Hotel in Toronto, Ontario.
Today in Conferences/Meetings...keeping you current
Receive free subspecialty "5-minute updates" via email
Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9
Repligen, 12/09/09
Allos Therapeutics' FOLOTYN Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
Allos Therapeutics, 12/08/09
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09